The large body of evidences suggesting a crucial role of the SHH signaling in oncogenesis of B-cell malignancies and the potential of Ixazomib to induce SHH signaling, prompted us to assess the PCs–MSCs crosstalk leading to a reduction of osteoblastogenesis in MM patients. This evidence concerns the gene SHH and Miyoshi myopathy.